Adhering to the current guideline standard for intraoperative nodal assessment in resected non–small cell lung cancer (NSCLC) ...

Skipping standard axillary lymph node dissection led to very low rates of axillary recurrence in patients with node-positive breast cancer who became node-negative following neoadjuvant chemotherapy, ...

The largest randomized trial of its kind to date found noninferior survival and better arm morbidity among patients with breast cancer who did not undergo completion axillary lymph node dissection.

Trial in progress update on ENGOT-cx8/GOG-3024/innovaTV 205: Addition of a new cohort with first-line (1L) tisotumab vedotin (TV) + pembrolizumab (pembro) + carboplatin (carbo) ± bevacizumab (bev) in ...

Omitting completion axillary lymph node dissection does not increase risk for death for patients with clinically node-negative breast cancer, but it does significantly improve arm distress.Data from ...

Extended dissection did not improve recurrence-free or overall survival, but it may have a bladder cancer-specific survival benefit possibly because it removes micrometastases. Extended lymph node ...

In a trial, selected patients with early non-small cell lung cancer did not benefit from mediastinal lymph node dissection (LND). Mediastinal LND resulted in longer surgeries, increased bleeding, and ...

A phase I study of ADXS-504, a cancer type specific immunotherapy, for patients with biochemically recurrent prostate cancer. Background: The therapeutic benefit of pelvic lymph node dissection (PLND) ...

Applies to most patients with one or two positive sentinel lymph nodes ...

Study finds lower mortality rates associated with excisions of higher numbers of lymph nodes in patients with intermediate- and high-risk prostate cancer. Removal of greater numbers of lymph nodes ...